AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on an innovative discovery by researchers of Osaka University. We specialize in R&D and practical application of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations.
We are also making every effort to develop the HVJ Envelope Vector(a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL).
We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.
Company Details
- Address
- 5-20-14 Shiba, Minato-Ku,tokyo 108-0014,japan
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- anges-mg.com
- HQ
- Minato-ku, Tokyo
Anges Mg, Inc Questions
Anges Mg, Inc's website is anges-mg.com
Anges Mg, Inc's LinkedIn profile is https://jp.linkedin.com/company/anges-mg-inc
Anges Mg, Inc's industry is
Pharmaceutical Manufacturing
Anges Mg, Inc's top competitors are
Kidswell Bio Corporation,
Chiome Bioscience,
Peptidream Inc.,
Sinbio,
Brightpath Biotherapeutics,
Anges Québec,
Sbi Biotech Co., Ltd.,
Kissei Pharmaceutical Co Ltd,
Hanavax,
ネクセラファーマ株式会社.
Anges Mg, Inc's categories are Pharmaceutical Manufacturing
